Priced Out of the Past: How Market Forces and Clinical Inertia Are Keeping Chloroquine Out of American Rheumatology Offices

There is something quietly paradoxical about the state of chloroquine in American rheumatology. A drug with more than seven decades of documented clinical use, a well-characterized safety profile, and a cost measured in dollars per month sits underutilized in a specialty that routinely prescribes biologics costing tens of thousands of dollars per year. Understanding why requires looking beyond pharmacology and into the economic, institutional, and cultural machinery that shapes how physicians prescribe — and how patients ultimately receive care.

A Drug That Earned Its Stripes Long Before the Modern Era

Chloroquine's entry into autoimmune medicine was not incidental. Clinicians first observed its anti-inflammatory properties in the mid-twentieth century, and systematic study confirmed meaningful benefits in conditions including systemic lupus erythematosus (SLE) and early rheumatoid arthritis. Its mechanisms — interference with lysosomal function, modulation of toll-like receptor signaling, and attenuation of cytokine production — are not merely theoretical. They underpin a body of clinical evidence that has, by most objective measures, held up well over time.

The Canadian Hydroxychloroquine Study, landmark SLE cohort analyses, and subsequent real-world data have collectively reinforced the drug's value as a disease-modifying agent. Chloroquine's close structural relative, hydroxychloroquine, has become a standard-of-care recommendation in lupus management from virtually every major rheumatology guideline body in the United States. Yet chloroquine itself — which predates hydroxychloroquine and carries a comparable mechanistic profile — receives comparatively little clinical attention, even where guidelines permit its use.

The Biologic Boom and the Displacement of Older Therapies

The late 1990s and early 2000s marked a seismic shift in rheumatology. The arrival of TNF-alpha inhibitors, followed by IL-6 antagonists, B-cell depleting agents, and JAK inhibitors, introduced therapeutic options that were genuinely transformative for patients with severe or refractory disease. Few clinicians would dispute their value in appropriate clinical contexts.

What is more difficult to justify, however, is the degree to which the biologic era reshaped prescribing culture across the entire spectrum of autoimmune disease severity — not just at its most treatment-resistant end. Industry-sponsored continuing medical education, aggressive pharmaceutical detailing, and the natural human preference for novelty collectively shifted clinical mindshare toward newer agents. Older drugs, including chloroquine, receded not because evidence turned against them, but because they stopped being actively promoted.

Health economists have a term for this phenomenon: therapeutic substitution driven by marketing rather than clinical superiority. When a generic drug with no commercial sponsor competes for physician attention against a branded biologic with a dedicated sales force, the outcome is rarely determined by the clinical literature alone.

What Rheumatologists and Patient Advocates Are Saying

Conversations within the rheumatology community reveal a nuanced picture. Many experienced clinicians acknowledge that chloroquine and hydroxychloroquine remain underappreciated relative to their evidence base, particularly for patients with mild-to-moderate lupus or early inflammatory arthritis who do not yet require immunosuppressive escalation.

Patient advocacy groups focused on lupus and related conditions have raised parallel concerns. For uninsured or underinsured Americans — a population disproportionately represented among lupus patients, given the disease's prevalence in Black and Hispanic women — the cost differential between antimalarials and biologics is not abstract. It is the difference between consistent disease control and rationed care. A monthly supply of generic chloroquine may cost a patient less than a single copayment for a biologic infusion.

Yet the barriers are not purely financial. Familiarity and comfort play a significant role in prescribing decisions. Physicians trained in the biologic era may have limited direct experience with antimalarial agents, reducing their confidence in initiating or optimizing these therapies. Without robust exposure during residency or fellowship, chloroquine can feel like unfamiliar territory even when guidelines support its use.

Regulatory Positioning and the Second-Line Stigma

Chloroquine's regulatory status in the United States adds another layer of complexity. While hydroxychloroquine carries FDA approval for lupus and rheumatoid arthritis, chloroquine's approved indications are narrower — primarily malaria prophylaxis and treatment, with extraarticular amebiasis. Its use in autoimmune conditions is largely off-label, a designation that, despite being clinically common, carries institutional and medicolegal weight that can discourage prescribing.

This regulatory asymmetry is somewhat arbitrary from a pharmacological standpoint, reflecting historical timing of approval applications rather than meaningful clinical differences between the two compounds. Nevertheless, the off-label designation functions as a soft barrier — one that affects insurance reimbursement, hospital formulary inclusion, and physician confidence alike.

The COVID-19 episode further complicated matters. Chloroquine's brief, politically charged moment in the pandemic spotlight — followed by a rapid and public repudiation based on rigorous trial data — left reputational residue that has little relevance to its established applications in rheumatology but may nonetheless color how some clinicians and patients perceive it.

The Formulary Problem and the Path Forward

Hospital and insurance formularies represent another structural obstacle. Formulary committees, while ostensibly evidence-driven, are also responsive to manufacturer relationships, rebate structures, and administrative convenience. Generic drugs with no industry advocate frequently find themselves disadvantaged in formulary negotiations — not excluded, but deprioritized in ways that affect prescribing defaults and patient access at the point of care.

Addressing these systemic gaps will require deliberate effort from multiple directions. Rheumatology training programs could do more to ensure that fellows develop genuine familiarity with antimalarial agents, including appropriate patient selection, dosing principles, and monitoring protocols. Professional societies could invest in disseminating evidence-based guidance that explicitly addresses the role of chloroquine alongside hydroxychloroquine, reducing the ambiguity that discourages use.

Perhaps most importantly, the broader conversation about drug pricing and therapeutic value in American medicine needs to make room for the possibility that older, cheaper, and well-evidenced drugs deserve sustained clinical attention — not as a compromise when newer options are unavailable, but as a legitimate first choice for appropriate patients.

A Question of Priorities

The underutilization of chloroquine in American rheumatology is not primarily a scientific failure. The evidence has been available, and in many respects it has been sufficient for decades. What has failed is the translation of that evidence into equitable prescribing practice — a translation distorted by market incentives, regulatory asymmetries, and the institutional tendency to conflate novelty with superiority.

For patients managing chronic autoimmune conditions on limited budgets, the stakes of this failure are concrete. Access to effective, affordable disease control is not a secondary consideration — it is the foundation upon which long-term health outcomes are built. Restoring chloroquine to its appropriate place in the rheumatology toolkit is, at its core, a question of whether American medicine is willing to let evidence lead where economics have not.